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OBJECTIVE—ADOPT (A Diabetes Outcome Progression Trial)
demonstrated that initial monotherapy with rosiglitazone pro-
vided superior durability of glycemic control compared with
metformin and glyburide in patients with recently diagnosed type
2 diabetes. Herein, we examine measures of b-cell function and
insulin sensitivity from an oral glucose tolerance test (OGTT)
over a 4-year period among the three treatments.
RESEARCH DESIGN AND METHODS—Recently diagnosed,
drug-naïve patients with type 2 diabetes (4,360 total) were treated
for a median of 4.0 years with rosiglitazone, metformin, or gly-
buride and were examined with periodic metabolic testing using
an OGTT.
RESULTS—Measures of b-cell function and insulin sensitivity
from an OGTT showed more favorable changes over time with
rosiglitazone versus metformin or glyburide. Persistent improve-
ments were seen in those who completed 4 years of monotherapy
and marked deterioration of b-cell function in those who failed to
maintain adequate glucose control with initial monotherapy.
CONCLUSIONS—The favorable combined changes in b-cell
function and insulin sensitivity over time with rosiglitazone ap-
pear to be responsible for its superior glycemic durability over
metformin and glyburide as initial monotherapy in type 2 diabe-
tes. Diabetes 60:1552–1560, 2011
I
n the UK Prospective Diabetes Study (UKPDS),
a progressive decline in b-cell function was the ma-
jor determinant of loss of glycemic control over time
in type 2 diabetes (1). However, differential effects
of diet, sulfonylurea, and metformin on insulin sensitivity
and b-cell function did not yield substantive differences in
the rates of increase in glycated hemoglobin (1).
Subsequently, thiazolidinediones were introduced that
primarily improve insulin sensitivity in the peripheral tis-
sues (2), while also affecting b-cell function by reducing
the demand to synthesize and release insulin. In contrast,
the biguanide metformin acts primarily to reduce hepatic
glucose production, whereas the sulfonylureas stimulate
insulin release by binding to their receptor on the b-cell
(2).
Given these different mechanisms of action, A Diabetes
Outcome Progression Trial (ADOPT) was designed to as-
sess whether initial monotherapy with the thiazolidine-
dione rosiglitazone could slow the rate of decline of b-cell
function in type 2 diabetes and associated loss-of-glucose
control, relative to metformin or sulfonylurea (glyburide)
(3). In ADOPT, rosiglitazone provided lower rates of
monotherapy failure and lower levels of fasting plasma
glucose and glycated hemoglobin, yielding superior dura-
bility of glycemic control than metformin or glyburide (4).
Measures of insulin sensitivity and b-cell function de-
termined from fasting and 30-min samples during an oral
glucose tolerance test (OGTT) allowed examination of
mechanisms by which each agent affected glycemic out-
comes. Herein, changes over time for these measures are
compared among the three treatment groups in the full
cohort and separately among those who either success-
fully completed or failed initially assigned monotherapy
over a period of 4 years. Joint vector plots are used to
display concomitant changes in secretory response and
insulin sensitivity over time with each therapy.
RESEARCH DESIGN AND METHODS
Subjects. ADOPT, a randomized, double-blind, parallel-group trial, enrolled
4,360 individuals with type 2 diabetes of up to 3 years’ duration who were drug-
naïve for glucose-lowering therapy (3). The protocol was approved by in-
stitutional review boards for each center, and subjects gave written, informed
consent to participate in the study.
Subjects were randomly assigned to double-blind, twice-daily treatment
with rosiglitazone (n = 1,456), metformin (n = 1,454), or glyburide (n = 1,441)
as initial monotherapy; nine subjects never received study medication. Medi-
cations were titrated, if fasting plasma glucose levels were 7.8 mmol/L or
more, to a maximum of 8 mg/day, 2 g/day, and 15 mg/day, respectively. Dose
reductions were permitted if adverse events occurred. The primary outcome
was the time to monotherapy failure on maximum-tolerated study drug dose,
deﬁned as a fasting plasma glucose .10 mmol/L on two successive occasions
or by independent adjudication (3).
Analyses were performed in the full cohort and separately in those who
completed their metabolic assessments at 4 years (4-year completer cohort)
and those who failed monotherapy before 4 years (monotherapy failure co-
hort).
Methods. Assessments were performed using standardized procedures at
baseline and then every 6 months for the duration of the study (3). Fasting
blood samples were drawn for measurement of metabolic variables, including
plasma glucose, HbA1c, and immunoreactive insulin levels. An abbreviated
75-g OGTT measuring glucose and immunoreactive insulin levels before and
30 min after glucose ingestion was performed at baseline and then every
6 months for the duration of the study.
Assays and calculations. All assays were performed at a central laboratory (3).
InsulinsensitivityandtheinsulinresponseobtainedfromtheOGTTwerethe
inverse of the fasting insulin concentration and the insulinogenic index, re-
spectively (5)—the latter a dynamic measure calculated as the ratio of the
incremental insulin and glucose responses over the ﬁrst 30 min of the test
From the
1Department of Medicine, Division of Metabolism, Endocrinology
and Nutrition, VA Puget Sound Health Care System and University of Wash-
ington, Seattle, Washington; the
2Biostatistics Center, George Washington
University, Rockville, Maryland; the
3Samuel Lunenfeld Research Institute,
Mount Sinai Hospital and University of Toronto, Ontario, Canada;
4San Antonio,
Texas;
5GlaxoSmithKline, King of Prussia, Pennsylvania; the
6Departments of
Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, Mich-
igan; the
7King’s College London School of Medicine, King’s College London,
London, U.K.; and the
8Diabetes Trials Unit, Oxford Centre for Diabetes,
Endocrinology and Metabolism, Oxford University, Oxford, U.K.
Corresponding author: Steven E. Kahn, skahn@u.washington.edu.
Received 18 October 2010 and accepted 8 February 2011.
DOI: 10.2337/db10-1392. Clinical trial reg. no. NCT00279045, clinicaltrials.gov.
*A complete list of the ADOPT Study Group can be found in N Engl J Med
2006;355:2427–2443.
 2011 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
1552 DIABETES, VOL. 60, MAY 2011 diabetes.diabetesjournals.org
ORIGINAL ARTICLE(insulin30 – insulin0/glucose30 – glucose0). Homeostasis model assessment
(HOMA) %S and HOMA %B were estimated using the HOMA2 model calculator
(http://www.dtu.ox.ac.uk/homa) (6).
Metabolic assessments were not conducted after subjects reached mono-
therapy failure or withdrew from study medication. Thus treatment group
differences in these measures over time may be inﬂuenced by the successive
culling of subjects reaching monotherapy failure. Thus sensitivity analyses
assessed the potential impact of bias.
Statistical methods. Of the 25,196 insulinogenic index values obtained
through the 4-year visit, 768 (3.05%) were #0. Although mathematically pos-
sible, such values are currently considered biologically implausible and were
treated as missing values. These implausible responses were observed in
637 subjects (average of 1.17 per such subject), of which 156 had a response
#0 at baseline necessitating their exclusion from the longitudinal analyses.
Of the 768 values, the median value was 29.81, 25% were ,21.34, 5% were
,2152, and 1% was ,21,021, and the minimum was 25,880. Finally, no asso-
ciation was observed between the fasting glucose concentration and values #0.
Wilcoxon rank sum test compared baseline variables between groups for
quantitative variables, and the contingency x
2 test for qualitative variables (7).
Normal errors longitudinal linear models (8) were used to estimate mean
levels of the parameters over time within groups up to 4 years of follow-up
using all available data. Mean change from baseline to 6 months described
the immediate impact of a therapy on outcomes. The average rate of change
from 6 months to 4 years was estimated from a linear contrast of the model-
estimated means over time.
Analyses of the reciprocal fasting insulin and insulinogenic index used the
natural log transformation to better approximate a normal distribution for
errors and homoscedasticity of variances, with the results presented as
geometric means 6 SE asymmetric limits, the latter obtained as exp
(means 6 SE of the log values). For these variables, mean percent change
over 6 months and mean percent change per year from 6 months to 4 years
are presented.
However, the longitudinal model results could be biased because subjects
with the most rapid decline in these metabolic measures (i.e., the steepest
slopes) have a shorter time to monotherapy failure and, therefore, contribute
fewer observations to estimation of the rate of change over time in the cohort.
In this setting, an unweighted average of the subject-speciﬁc slopes provides
a less biased estimate of the overall rate of change (9).
A two-sided P # 0.05 was considered statistically signiﬁcant.
RESULTS
Demographic and metabolic variables. Table 1 presents
the baseline values for all 4,351 patients, the 2,112 who
completed 4 years of follow-up, and the 526 who failed
monotherapy before 4 years, of whom 11% were followed
for less than 1 year, 25% for 1–2 years, 30% for 2–3 years,
24% for 3–4 years, and 10% for 4 years or more. The
monotherapy failure cohort was younger, more obese, and
initially had a greater waist circumference, higher mean
fasting plasma glucose and HbA1c levels, and a lower sys-
tolic blood pressure than those completing 4 years on study
medication. They also had lower median b-cell function
scores at baseline, determined as the insulinogenic index
and HOMA %B.
Only patients with a baseline and follow-up evaluation
of each outcome measure (insulinogenic index and re-
ciprocal fasting insulin) contributed data to the longitu-
dinal analyses of that measure described below. The
longitudinal analyses of the HOMA values are not pre-
sented because they have been published previously (4).
Early insulin response (insulinogenic index) for the
full cohort. The longitudinal model estimated mean
insulinogenic index over up to 4 years of follow-up within
each treatment group for the full cohort is presented in
Fig. 1A. Table 2 shows the short-term (acute) effect of
therapy characterized as the mean percent change from
baseline to 0.5 years and the long-term (chronic) effect
TABLE 1
Baseline demographic and metabolic variables in the full cohort, those completing 4 years, and those with monotherapy failure before
4 years
All
subjects
4-Year
completer cohort
4-Year monotherapy
failure cohort
P value
4-Year completers
vs. monotherapy
failures
n 4,351 2,112 526
Age (years) 56.5 6 10.0 58.0 6 9.4 52.2 6 9.7 ,0.025
Males (n, %) 2,511 (57.7) 1,251 (59.2) 321 (61.0) N.S.
Time since diagnosis of diabetes (years)
,1 1,961 (4.1) 929 (44.0) 237 (45.1) N.S.
1–2 2,233 (51.3) 1,100 (52.1) 274 (52.1) N.S.
.2 157 (3.6) 83 (3.9) 15 (2.9) N.S.
GAD-positive 175 (4.0) 92 (4.4) 25 (4.8) N.S.
BMI (kg/m
2) 32.2 6 6.3 31.8 6 6.0 33.2 6 6.4 ,0.025
Waist circumference (cm) 105.5 6 14.7 104.8 6 13.7 108.0 6 16.1 ,0.025
Waist-to-hip ratio 0.95 6 0.09 0.95 6 0.09 0.96 6 0.09 N.S.
Blood pressure (mmHg)
Systolic 132.9 6 15.5 133.3 6 15.4 131.1 6 15.9 ,0.025
Diastolic 79.6 6 8.8 79.3 6 8.6 79.7 6 9.2 N.S.
Fasting plasma glucose (mmol/L) 8.4 6 1.5 8.2 6 1.3 9.1 6 1.7 ,0.025
HbA1c (%) 7.4 6 0.9 7.2 6 0.9 7.7 6 1.0 ,0.025
Fasting insulin (pmol/L) 150.7 6 111.0
122.0 (84.0, 186.0)
147.9 6 113.2
120.0 (84.0, 179.4)
148.5 6 100.4
126.0 (84.0, 186.0)
N.S.
1/Fasting insulin (pmol/L
21 3 10
23) 8.20 (5.38, 11.90) 8.33 (5.57, 11.90) 7.94 (5.38, 11.90) N.S.
HOMA %S 33.4 (22.6–48.2) 34.6 (23.5–49.4) 31.5 (21.8–47.7) N.S.
Insulinogenic index (pmol/L per mmol/L) 32.0 (17.9, 57.4) 33.2 (19.2, 58.9) 26.1 (12.5, 47.7) ,0.025
HOMA %B 68.4 (52.0–88.3) 70.4 (53.4–90.4) 60.3 (44.5–79.7) ,0.025
Continuous data are expressed as means 6 SD and/or median (ﬁrst, third quartile). For time since diagnosis of diabetes and GAD-positive,
data are n (%). P values were adjusted for two comparisons using the Bonferroni method. HOMA %S and HOMA %B were determined using the
HOMA calculator (www.dtu.ox.ac.uk/homa). N.S., nonsigniﬁcant.
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from 0.5 to 4 years. The longitudinal analysis of the log
values provides estimates of the percent change over time.
A signiﬁcantly higher acute change in the insulinogenic
index over the ﬁrst 6 months was observed with glyburide
versus rosiglitazone, with there being no change with
rosiglitazone and an intermediate change with metformin.
Thereafter, glyburide was associated with a signiﬁcantly
faster rate of decline (negative slope) versus rosiglitazone
(11.1 vs. 6.0% per year), with metformin as the interme-
diate. The different rates of decline meant that, beyond
24 months, the mean levels with glyburide were lower than
those in the other groups. The unweighted mean slope
analysis demonstrated similar differences between groups.
Insulin sensitivity (1/fasting insulin) for the full co-
hort. Figure 1B presents the longitudinal model estimated
mean reciprocal fasting insulin from the OGTT over time for
4 years of follow-up within each treatment group for the full
cohort. Table 2 shows the short- and long-term effects of
therapy on this measure.
Rosiglitazone produced a signiﬁcantly greater increase
over the ﬁrst 6 months in the reciprocal fasting insulin than
did either comparator, with glyburide initially decreasing
by 9.2% over this period. This ratio then increased over
time in all groups with no signiﬁcant differences between
groups. However, the unweighted analysis showed a sig-
niﬁcantly greater increase over time with rosiglitazone
than either comparator, suggesting that the lesser differ-
ences between groups observed in the longitudinal model
analysis could be attributed to the effects of early termi-
nation of follow-up because of monotherapy failure.
OGTT measures in the 4-year completer cohort.
Among those in the completer cohort, Fig. 2A and Table 3
indicate that the insulinogenic index did not increase sub-
stantially over the ﬁrst 6 months and then declined at a sig-
niﬁcantly faster rate with glyburide than with rosiglitazone.
The pattern of changes in insulin sensitivity is shown in
Fig. 2B and Table 3. The pattern in the completers was
similar to that in the full cohort. There was a signiﬁcantly
greater improvement at 6 months with rosiglitazone than
with either glyburide or metformin, and thereafter, there
was also a signiﬁcantly greater rate of increase over time
with rosiglitazone than with glyburide, with those with
metformin being intermediate.
FIG. 1. Baseline adjusted geometric mean levels in the full cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic
measure of the early insulin response (A; insulinogenic index; insulin30 2 insulin0/glucose30 2 glucose0) and insulin sensitivity (B; 1/fasting in-
sulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (6 SE asymmetric limits).
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cohort. Subjects who ultimately failed had lower levels of
the insulinogenic index at baseline (Fig. 3A) than those
who completed (Fig. 2A). Glyburide produced a small in-
crease at 6 months, whereas rosiglitazone had little effect
(Fig. 3A and Table 3). Thereafter, the insulinogenic index
declined, equally so in all groups.
Among failures, there was a much greater acute increase
in 1/fasting insulin with rosiglitazone than with either
metformin or glyburide, but thereafter, the rate of increase
was similar among groups (Fig. 3B and Table 3). The
failure cohort started at approximately the same levels as
the completer cohort, but the increase with rosiglitazone
was less. Thereafter, 1/fasting insulin increased among
failures at approximately the same rate as seen with com-
pleters.
Vector plots of OGTT measures. Figure 4A–C displays
the concomitant changes over time in the relationship
between the insulinogenic index and 1/fasting insulin for
the full, completer, and monotherapy failure cohorts, re-
spectively. This relationship depicts the pattern of changes
in glucose metabolism over time and is termed herein
vector plots.
In each case, the concave line represents the known
nonlinear relationship between a measure of b-cell func-
tion and insulin sensitivity at baseline (10–12) and is based
on the linear regression between log-transformed insulino-
genic index and 1/fasting insulin values. The single dot on
the line, which is the origin for each vector, shows the
common mean values for these two measures in all three
treatment groups, i.e., for the whole cohort, an insulino-
genic index of 33.1 pmol/L per mmol/L and a 1/fasting
insulin of 8.2 pmol/l
21 3 10
23. This point and each sub-
sequent one is a measure of the joint action of insulin
sensitivity and b-cell function over time and is commonly
known as the disposition index (12). The overall mean is
used because the baseline covariate-adjusted longitudinal
analyses presented in prior ﬁgures assume that all groups
start with a common baseline value.
Starting from this common point, joint geometric means
for insulinogenic index and 1/fasting insulin within each
group are plotted for the ﬁrst 6-month visit and, thereafter,
each annual anniversary visit. These are the same means
as presented separately in Figs. 1A and B,2 A and B, and
3A and B for the whole 4-year completer and 4-year
monotherapy failure cohorts, respectively. Movement of
the joint mean values up or down represents changes in
b-cell function, and movement of the joint means left or
right represents changes in insulin sensitivity over time.
Mean values remaining above the concave line represent
improvements in glucose metabolism from the level at
baseline, whereas those falling below the line represent
deterioration in glucose metabolism. Furthermore, the
greater the movement away from the concave line, the
larger the difference in overall glucose metabolism.
In the full cohort (Fig. 4A), there was a small acute
beneﬁcial effect with glyburide on the insulin response
(shift upward) but a decrease in insulin sensitivity (shift to
the left), so that overall glucose metabolism was not im-
proved relative to the concave line. Thereafter, the insu-
linogenic index fell (shift downward), whereas 1/fasting
insulin increased (shift rightward), but at a rate too slow
to compensate for the loss in insulin response (hence,
the values remain below the baseline regression line). In
contrast, with rosiglitazone and metformin, there is a ben-
eﬁcial effect that continues over time, more so with rosi-
glitazone. Although rosiglitazone had no acute effect on
the insulinogenic index over the ﬁrst 6 months, it had
TABLE 2
Changes in OGTT-derived measures of b-cell function (insulinogenic index) and insulin sensitivity (1/fasting insulin) for the full cohort
from baseline to 0.5 years and rates of change among means from 0.5 to 4 years based on a longitudinal model adjusted for baseline
factors
Variable Rosiglitazone Metformin Glyburide
P value
Rosiglitazone vs.
metformin
Rosiglitazone vs.
glyburide
Insulinogenic index (pmol/L per mmol/L)
n 1,125 1,124 1,060 ——
Mean %change from
0 to 0.5 years 0.0 (23.9, 4.1) 2.5 (21.5, 6.7) 6.6 (2.3, 11.1) 0.3826 0.0249
Rate of change from
0.5 to 4 years
(% per year) 26.0 (27.2, 24.8) 27.4 (28.5, 26.2) 211.1 (212.3, 29.8) 0.1133 ,0.0001
Unweighted mean
slope (% per year) 28.0 (29.5, 26.4) 28.8 (210.3, 27.2) 213.2 (215.0, 211.4) 0.4798 ,0.0001
1/Fasting insulin (pmol/L
21 3 10
23)
n 1,255 1,256 1,187 ——
Mean %change
from 0 to 0.5 years 25.7 (22.8, 28.7) 13.5 (10.9, 16.2) 29.2 (211.4, 27.0) ,0.0001 ,0.0001
Rate of change from
0.5 to 4 years
(% per year) 6.5 (5.8, 7.2) 5.9 (5.2, 6.7) 5.5 (4.7, 6.3) 0.2898 0.0822
Unweighted mean
slope (% per year) 6.9 (6.1, 7.8) 5.3 (4.4, 6.3) 5.2 (4.1, 6.2) 0.0176 0.0128
For the log-transformed insulinogenic index and reciprocal fasting insulin, results are presented as a percentage change from baseline and
mean rates of change (percent per year) 6 95% conﬁdence limits. The unweighted mean rate of change (mean slopes) over 0.5 to 4 years are
also listed. Changes from baseline, or rates of change, for which the 95% conﬁdence limits do not bracket zero are statistically signiﬁcantly
different at the 0.05 level, without adjustment for multiple tests of signiﬁcance.
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thereafter, the rate of further increase in the reciprocal
insulin more than compensated for the decline in the in-
sulinogenic index. Thus, the joint means show the greatest
distance from the baseline level in keeping with the ob-
servation that rosiglitazone produced a more favorable
long-term improvement in glucose metabolism than either
comparator.
The vector plot for the 4-year completer cohort (Fig. 4B),
as in the full cohort, shows that rosiglitazone produced
a more favorable long-term improvement in glucose metab-
olism than either of the comparators. These results are
similar both qualitatively and quantitatively to those observed
in the full cohort.
The vector plot for the 4-year monotherapy failure co-
hort (Fig. 4C) shows an initial improvement in glucose
metabolism in all three groups that then rapidly dissipates,
with the subjects returning to their baseline status, on
average, by 18–24 months, and then worsening further.
The fall below the baseline regression line with all treat-
ments is in keeping with disease progression and these
subjects ultimately reaching the monotherapy failure end
point. These results are both qualitatively and quantitatively
different from those of the 4-year completer and full cohorts.
DISCUSSION
Type 2 diabetes is characterized by a progressive loss of
b-cell function that is represented by deteriorating mea-
sures of insulin response relative to the prevailing insulin
sensitivity (10–13), resulting in deteriorating glycemic
control (1,13). This is best demonstrated by the loss of
b-cell function over time in individuals who progress from
states of impaired glucose metabolism to diabetes (14,15).
Thus, preserving the ability of the b-cell to secrete insulin
is thought to be critical to preventing the inexorable loss of
glucose control.
ADOPT allowed the systematic, prospective evaluation
of changes in glucose metabolism over a period of 4 years
in a large cohort of recently diagnosed type 2 diabetic
subjects randomized to initial monotherapy using rosigli-
tazone, metformin, or glyburide. In the ﬁrst 6 months, as
anticipated, glyburide increased stimulated insulin release
during the OGTT but did not change insulin sensitivity.
FIG. 2. Baseline adjusted geometric mean levels in the 4-year completer cohort within each treatment group over 4 years of follow-up for OGTT-
derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 2 insulin0/glucose30 2 glucose0) and insulin sensitivity
(B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (6 SE asymmetric
limits).
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small beneﬁcial effect on b-cell function following glucose
ingestion. Rosiglitazone had similar effects to metformin,
but of greater magnitude. Whether the beneﬁcial effects of
rosiglitazone and/or metformin on the b-cell are indirect as
a result of their ability to improve insulin sensitivity or
result from a direct action on the b-cell, as suggested by
some in vitro studies (16,17), cannot be determined from
these analyses.
Further differences emerged beyond the ﬁrst 6 months.
The insulinogenic index fell at the greatest rate with gly-
buride but at the lowest rate with rosiglitazone, whereas
metformin was intermediate. Concurrently, insulin sensi-
tivity showed a long-term beneﬁcial change with all three
medications, although the change with glyburide was less
than with rosiglitazone. This change with glyburide may be
the result of alleviation of glucose toxicity (18).
This analysis represents the ﬁrst longitudinal assess-
ment of measures involved in determining glucose me-
tabolism in a cohort of individuals with type 2 diabetes
followed for a prolonged period in a large, multicenter,
clinical trial. The effective evaluation of the time course of
b-cell function and insulin sensitivity was allowed by the
selection of a glycemic level of 10 mmol/L to unequivocally
represent monotherapy failure.
It is now well accepted that knowledge of the concom-
itant insulin sensitivity is required to accurately evaluate
b-cell function (10–13). Thus, vector plots of the joint
changes in OGTT measures of insulin response and insulin
sensitivity were used to describe changes in b-cell function
over time. These highlight the importance of this interplay
between the insulin response and insulin sensitivity and how
the relationship between these two parameters changes
over time with all three treatments. These changes are
different not only in magnitude but also in nature, with the
most favorable changes occurring with rosiglitazone in
keeping with improvements in both b-cell function and
insulin sensitivity.
These analyses used indirect measures of the b-cell and
insulin sensitivity. The dynamic measure of insulin release
was computed from two glucose and insulin pairs and the
estimate of insulin sensitivity from the fasting insulin level.
Although both these measures include fasting insulin, they
failed to show a substantial correlation at baseline, R
2 =0 . 2 9 ,
a level far below what would be considered as collinearity
(19). Thus, this OGTT measure of insulin release alone is far
from redundant with the measure of insulin sensitivity, and
examination of joint changes in the two measures provides
a more complete picture of disease progression over time
than does examination of either in isolation. Furthermore,
joint changes in the OGTT measures are in keeping with
different responses to therapy and an overall preservation of
b-cell function that is greatest with rosiglitazone and least
with glyburide.
Additional analyses were performed by examining the
526 subjects who failed monotherapy and the 2,112 that
did not during 4 years of follow-up. At baseline, those who
ultimately failed were younger and metabolically in a more
advanced state. The results among those who did not fail
closely resemble those for the full cohort, whereas among
those who ultimately failed monotherapy, all three medi-
cations demonstrated a short-term improvement in glucose
metabolism manifest as a change in the vector plot, such
that it was above the concave line. In those who failed
monotherapy, the ﬁnal point in each treatment group is
equidistant from the curve determined using the baseline
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pair of insulin release and insulin sensitivity measures rep-
resent a deterioration in glucose metabolism associated
with a fasting glucose of 10 mmol/L.
Analyses of the 4-year completer and 4-year mono-
therapy failure cohorts demonstrated beneﬁcial effects of
rosiglitazone versus either comparator or the lack of
beneﬁcial effects among those who failed. These outcomes
are directly explained by the presence or absence, respec-
tively, of beneﬁcial effects jointly on both b-cell function and
insulin sensitivity. Thus, the beneﬁcial effects of rosiglita-
zone on the durability of glycemic control are explained by
changes in determinants of glucose metabolism over time.
The longitudinal analyses within the full cohort may be
biased because of the truncation of follow-up assessments
in those who failed monotherapy. Additional sensitivity
analyses conducted to allow for such bias showed little
difference from those in the longitudinal analyses. The
analyses within the completer and failure cohorts also
suggest that had there been complete follow-up of all sub-
jects up to 4 years, regardless of monotherapy failure or not;
the overall beneﬁcial effects observed with rosiglitazone
would be expected to be diluted by the lack of a sustained
beneﬁcial effect among those who failed. However, given
the smaller number of such subjects, the overall beneﬁ-
cial effects observed in the full cohort would still apply.
In ADOPT, we chose to obtain measures of b-cell
function and insulin sensitivity that were the most practi-
cal to institute across the many clinics involved in the
study. This approach, of course, meant that we did not use
more sophisticated and precise measures of insulin sen-
sitivity. However, we do not believe that this severely
limits our ﬁndings because, although glyburide stimulates
insulin release and we may have overestimated the decrease
in insulin sensitivity, the rate of change in the insulinogenic
index over time was greatest with the sulfonylurea. This
change can be associated with the most rapid decrease in
b-cell function and thus more monotherapy failure.
In 3% of tests, the value for the insulinogenic index was
#0, with a similar percentage applicable to the values at
each visit and with a minority of subjects having only one
such value (if any). However, it did not appear to be oc-
curring in subjects who had more severe diabetes because
we failed to demonstrate a relationship between the fasting
FIG. 3. Baseline adjusted geometric mean levels in the 4-year monotherapy failure cohort within each treatment group over 4 years of follow-up for
OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 2 insulin0/glucose30 2 glucose0) and insulin
sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (6 SE
asymmetric limits).
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This is in line with a previous observation of ours demons-
trating that these negative responses occur not only in
subjects with diabetes but also in those with normal and
impaired glucose tolerance (20). It is noteworthy that a
negative ﬁrst-phase insulin response to intravenous glucose
has been observed in diabetic subjects with the greatest
elevation in glucose (21), suggesting that, in this instance, it
may be a manifestation of severely impaired b-cell function.
Although further studies will be required to better un-
derstand whether there is a physiological explanation for
an insulinogenic index #0, we believe that for the purpose
of estimating insulin release for large clinical studies, these
responses are not likely to represent a major limitation and
that the measure should be used.
Although the study cohort was broadly representative of
patients with type 2 diabetes diagnosed within 3 years,
they were selected to have a fasting glucose concentration
between 7.0 and 10.0 mmol/L without medication. Thus,
individuals who were more hyperglycemic or already re-
quired oral therapy would have been excluded. Further-
more, since ADOPT was initiated, there has been a move
toward tighter glucose control. Despite this, we believe
that our ﬁndings regarding b-cell function and insulin
sensitivity would have been similar if a fasting glucose
,10 mmol/L was used and would, thus, be applicable to
therapy today. This belief is based on our observation that
the monotherapy failure outcome was similar if we re-
stricted the analysis to an outcome of a fasting glucose
.7.8 mmol/L in subjects who started below this threshold (4).
In summary, the different evolving relationships be-
tween b-cell function and insulin sensitivity observed over
time explain the propensity to either maintain adequate
glycemic control with the initial monotherapy or to fail.
Differential changes in b-cell function and insulin sensi-
tivity, i.e., in glucose metabolism, are responsible for the
different degrees of glycemic durability observed with
rosiglitazone, metformin, and glyburide in ADOPT, with
rosiglitazone providing the most favorable changes in both
parameters and greatest durability over time.
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